secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001516551-23-000018
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience closes sale of Verdélite Sciences for $9.48M; receives $5.60M cash at closing
--------------------------------------------------------------------------------

- Sold wholly owned subsidiary Verdélite Sciences and 88k sq ft cannabis facility in St-Eustache, Quebec to C3 Souvenir Holding.
- Cash proceeds of $5.60M received on Feb 10, 2023; total deal value $9.48M with deferred payments through 2026.
- Deferred payments: $0.12M by June 2023, $0.37M in 5 monthly installments starting Dec 2023, plus $2.80M in three equal anniversary payments.
- CEO states the closing payment extends operating runway and supports Phase 2 trial for SBI-100 OE (glaucoma drug).
- C3 acquires Emerald's Souvenir brand; deal brokered by Hyde Advisory and AMK Advisory Services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000018/0001516551-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000018/skye-20230209.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer